This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Register by January 24 to save up to $1200

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 19-22, 2025
Manchester Grand Hyatt San DiegoSan Diego, CA
Book Now
Menu
Book
Key Sessions
Laura Sepp-Lorenzino, PhD
Realizing the Promise of CRISPR Therapeutics
Intellia Therapeutics
Hiroaki Suga, PhD
RaPID Display and Selection of Pseudo-natural Products
University of Tokyo
Art Levin, PhD
State of the Art: A Look at Oligonucleotide Therapeutics Past, Present, and Future
Avidity Biosciences
Lotte Bjerre Knudsen, PhD
The Science Behind the GLP-1 Medicines: A Historic View and Future Outlook
Novo Nordisk A/S
Muthiah (Mano) Manoharan, PhD
“I Love Conjugates”: The GalNAc Revolution and Its Impact on Oligonucleotide Therapeutic Development
Alnylam Pharmaceuticals
Sam Tsimikas, MD
Clinical Update on Oligonucleotides for Cardiovascular Disease
Ionis Pharmaceuticals
keyboard_arrow_right

Main Conference - Day 1 Keynote Sessions (May 20)

keyboard_arrow_leftSearch & Filter
search
Main Conference - Day 1 Keynote Sessions (May 20)
search
6:30am - 7:30am
Registration
Breakfast Spotlight Presentations
Showing 3 of 3 Streams
7:30am - 8:00am
Technical Application of Continuous Chromatography and Mixer-Type Lyophilization in Peptide and Oligonucleotide Downstream Processes
  • Yoshitaka Nemoto - Vice President R&D, PeptiStar
7:30am - 8:00am
LNP Production for mRNA Vaccines, Therapeutics, and for Gene Editing – Proof of Concept for a Versatile Process
  • Thomas Vrucina - Deputy Head Liposome Technology, Polymun Scientific
7:30am - 8:00am
Synthetic Peptide CMC Development and Experiences
  • Susan Li, PhD - Peptide Chief Scientist, Asymchem
Showing 1 of 1 Streams
8:10am - 8:15am
Chairperson’s Remarks: Keynote Day 1
8:15am - 9:00am
The Science Behind the GLP-1 Medicines: A Historic View and Future Outlook
  • Lotte Bjerre Knudsen, PhD - Chief Scientific Advisor & Head of GLP-1 CoE, Novo Nordisk A/S
9:00am - 9:45am
“I Love Conjugates”: The GalNAc Revolution and Its Impact on Oligonucleotide Therapeutic Development
  • Muthiah (Mano) Manoharan, PhD - Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist, Alnylam Pharmaceuticals
9:45am - 10:15am
Networking Refreshment Break
Morning Keynote Session
Showing 1 of 1 Streams
10:15am - 11:00am
Realizing the Promise of CRISPR Therapeutics
  • Laura Sepp-Lorenzino, PhD - Executive Vice President, Chief Scientific Officer, Intellia Therapeutics
11:00am - 11:45am
Oligonucleotide Therapeutics: Current Challenges and Opportunities
  • David Corey, PhD - Professor of Pharmacology and Biochemistry, UT Southwestern; Past President, OTS
11:45am - 12:05pm
Transition to Spotlight Presentation/Panel Luncheons
Spotlight Presentation Luncheons
Showing 6 of 6 Streams
12:05pm - 12:35pm
Biodegradable Lipid Nanoparticles with Tunable Immunogenicity

The immunogenicity of ionizable lipids is a significant issue in applications such as gene editing or mRNA therapeutics. We have developed a novel chemical family of biodegradable lipids (COATSOME® SS Series) that exhibit exceptional stability in the circulating state and only break down when triggered by specific stimuli present in the cytosol. We will present further data on the cytokine profile, toxicity, and efficacy of COATSOME® SS Series in multiple animal models.

  • Syed Reza, MD, PhD - Scientific and Sales Consultant, NOF Corporation
12:05pm - 12:35pm
Novel Approaches to Minimize dsRNA in mRNA Production
  • Jon Cooper, PhD - Vice President – mRNA Sciences and Analytical Development, Aldevron
12:05pm - 12:35pm
Advancing mRNA Therapeutics: Novel Modification Strategies for Improved Performance
  • Chunping Xu, Ph.D - Senior Director of Chemistry R&D, TriLink BioTechnologies
12:05pm - 12:35pm
Nitto Avecia Spotlight Presentation
12:05pm - 12:35pm
Bachem Spotlight Presentation
12:35pm - 12:55pm
Short Networking Break
Afternoon Keynote Session
Showing 1 of 1 Streams
12:55pm - 1:00pm
Chairperson’s Remarks: Keynote Day 1
1:00pm - 1:45pm
State of the Art: A Look at Oligonucleotide Therapeutics Past, Present, and Future
  • Art Levin, PhD - Retired CSO, Avidity Biosciences
1:45pm - 2:30pm
Clinical Update on Oligonucleotides for Cardiovascular Disease
  • Sam Tsimikas, MD - Senior Vice President of Global Cardiovascular Development, Ionis Pharmaceuticals
2:30pm - 3:30pm
Grand Opening of Poster and Exhibit Hall and Networking Refreshment Break
Showing 1 of 1 Streams
3:30pm - 4:15pm
RaPID Display and Selection of Pseudo-natural Products

This lecture discusses a new development of display format for the discovery of pseudo-natural products against intracellular targets of protein. The technology enables us to access unexplored chemical space with cell membrane permeability of macrocycles.

  • Hiroaki Suga, PhD - Professor of Chemistry, School of Science, University of Tokyo
4:15pm - 5:00pm
Panel Discussion: Addressing the Challenges of Bringing New Therapeutic Modalities to Market: Technical and Regulatory Considerations
  • Rachael Anatol - Deputy Super Office Director, Office of Therapeutic Products, CBER, FDA
5:00pm - 6:30pm
Networking Reception in the Poster and Exhibit Hall
Pre-Conference Day (May 19)
NextMain Conference - Day 2 (May 21)
Filter
Streams
Choose Day